# GLP-1 / Type 2 Diabetes Market: The T1D App's Bigger Play *Generated: April 4, 2026 | Rob Lobster 🦞* ## Executive Summary Joe's T1D blood sugar prediction app has a built-for-Keli origin story. But the **massive money is in the GLP-1 / Type 2 / weight loss market** — and the timing couldn't be better. The GLP-1 market is projected to reach **$101-200 billion by 2030-2035**, with 25-30 million Americans on GLP-1 treatment by 2030. These users desperately need exactly what Joe's app does: wearable-driven metabolic insights and glucose prediction. This analysis sizes the opportunity and maps the expansion path. --- ## The GLP-1 Explosion: By the Numbers ### Market Size (Multiple Sources, Cross-Referenced) - **2025:** $52-70 billion (GLP-1 receptor agonist market globally) - **2026:** $101 billion (Roots Analysis) - **2030:** $200 billion (J.P. Morgan forecast for global incretin market) - **2035:** $66.6 billion (obesity GLP-1 alone, Precedence Research) to $180 billion (total GLP-1, Roots Analysis) - **CAGR:** 10.9-12.8% through 2033-2035 ### User Growth - **2023:** 5 million Americans on GLP-1s - **2024:** 6 million - **2025:** 10 million - **2026:** ~20 million (projected, with oral GLP-1 launch) - **2030:** 25-30 million Americans (J.P. Morgan) ### Key 2026 Catalysts 1. **Oral GLP-1 pills launched** — Novo Nordisk's oral Wegovy approved late 2025, Lilly's oral expected April 2026 2. **Medicare/Medicaid coverage expanding** — BALANCE pilot program, $50/month cap for seniors 3. **55% of commercial employers now cover GLP-1s** for obesity (up from ~30% in 2023) 4. **GLP-1 supply shortages resolved** — Wegovy and Zepbound fully available --- ## Why GLP-1 Users Need Joe's App ### The Problem GLP-1 Users Face GLP-1 medications cause dramatic metabolic changes: - Appetite suppression → calorie reduction (21% fewer calories per J.P. Morgan) - Insulin sensitivity changes → glucose variability - Muscle mass loss risk → need to monitor body composition - **Stress-induced cortisol spikes** still cause glucose excursions even ON GLP-1s - Users need to understand which foods/activities work WITH their medication ### What Joe's App Does That Others Don't **The core differentiator (from the T1D MVP roadmap, Apr 3):** - **PREDICTION, not just tracking** — stress-based glucose forecasting before spikes happen - CGM + Oura Ring (HRV/stress) data fusion - Nobody else is using wearable stress data to PREDICT glucose events for GLP-1 users ### The Competitive Landscape (GLP-1 Digital Health) **Direct CGM+Coaching Apps:** | Company | Focus | GLP-1 Support | Prediction? | Wearable Integration | |---------|-------|---------------|-------------|---------------------| | Signos | CGM + weight loss | Yes | Limited | CGM only | | Levels | Metabolic wellness | No specific | No | CGM only | | Nutrisense | Nutrition coaching | Emerging | No | CGM only | | January AI | AI glucose prediction | No specific | **Yes** (meal-based) | CGM only | | Veri | Metabolic flexibility | No specific | No | CGM only | | Dario | Multi-condition | Yes | No | CGM + BP | | **Joe's App** | **Stress-glucose prediction** | **Expansion target** | **Yes (stress-based)** | **CGM + Oura/Apple Watch** | **Key gaps in the market:** 1. **Nobody combines CGM + HRV/stress data for prediction** — this is Joe's white space 2. January AI does meal-based prediction but NOT stress-based — different mechanism entirely 3. Most competitors are CGM-only — they miss the stress/cortisol dimension 4. **Weight Watchers** launched a GLP-1 program (Dec 2025) but it's behavioral coaching, not biosensor-driven 5. **Shotsy and Weightly** are just shot trackers — no intelligence layer --- ## The Expansion Strategy: T1D → GLP-1/T2D → General Metabolic Health ### Phase 1: T1D (May-October 2026) — *Already planned* - Build for Keli, validate with real T1D users - Establish the stress-glucose prediction engine - FDA general wellness pathway (avoid clinical claims) - **TAM:** ~2M Type 1 diabetics in the US ### Phase 2: GLP-1 Companion App (Q1 2027) - **Rebrand/expand:** "Predict" → metabolic health platform - Add GLP-1-specific features: - Medication logging (dose, timing, side effects) - Weight/body composition tracking integration - Muscle preservation alerts (GLP-1 muscle loss monitoring) - Food-glucose correlation (which meals work with your medication) - **Marketing angle:** "See how your body responds to GLP-1 in real time" - **TAM:** 20-30M GLP-1 users by 2027-2030 ### Phase 3: General Metabolic Health (2028+) - Non-diabetic metabolic optimization (the Levels/Signos market) - Athletic performance - Longevity/preventive health - **TAM:** 100M+ health-conscious Americans --- ## Revenue Model Evolution ### T1D Phase (2026) - Freemium + $9.99/month subscription - Target: 1,000 paid users by end of 2026 = $120K ARR - Claude API costs: ~$0.50-1.00/user/month ### GLP-1 Phase (2027) - $14.99/month subscription (premium positioning) - B2B channel: Partner with telehealth GLP-1 prescribers (Hims, Ro, Found, etc.) - **These companies would PAY for a biosensor companion app** to reduce churn and improve outcomes - Revenue share: $5-10/user/month from telehealth partners - Target: 10,000 paid users by end of 2027 = $1.8M ARR ### Scale Phase (2028+) - Enterprise/employer wellness programs - Insurance company partnerships (GLP-1 adherence = lower claims) - Target: 50,000+ users = $9M+ ARR --- ## Strategic Implications for Joe ### This Changes the Investment Thesis The T1D app as a "love project for Keli" is beautiful. But with the GLP-1 expansion lens, it becomes: 1. **A venture-backable business** — $200B GLP-1 market growing 10%+ CAGR 2. **Potential acqui-hire target** — Dexcom, Oura, Novo Nordisk, and telehealth companies would all want this tech 3. **Personal alignment** — Joe is researching GLP-1s himself (weight loss), Keli has T1D. Both use cases in one household. 4. **Joe's 5-7 year window** applies — even if a T1D cure arrives (Vertex's zimislecel), GLP-1/T2D/obesity market only grows bigger ### The Dexcom-Oura Investment (From Apr 3 Research) - Dexcom invested $75M in Oura Ring — this VALIDATES Joe's thesis - They're building the CGM+wearable pipeline - Joe's app sits on TOP of that pipeline as the intelligence/prediction layer - **He doesn't compete with Dexcom or Oura — he makes their products more valuable** ### Key Risk: Dexcom/Oura Build It Themselves - Mitigated by: Speed to market. Joe can have an MVP by July 2026 (per Apr 3 roadmap) - Large companies are slow to build consumer apps (Dexcom's app UX is notoriously bad) - If they DO build it, acquisition is the exit strategy (not competition) --- ## Recommended Next Steps 1. **Don't change the Phase 1 plan** — build for T1D/Keli first (May-Jul 2026). This is the validation. 2. **Design the data model to accommodate GLP-1 from day one** — medication tracking, weight/body comp fields, flexible enough for expansion 3. **File "Predict" or similar app name trademark** ($500-1,500) 4. **Start tracking GLP-1 telehealth companies** as future partners: - Hims & Hers ($HIMS) - Ro - Found - Calibrate - Noom (now offers GLP-1 programs) 5. **Consider:** If the T1D MVP works, the GLP-1 expansion pitch could attract angel/seed funding ($250K-500K) to hire a developer and accelerate --- ## The Bottom Line Joe's T1D app isn't a niche product — it's a **metabolic health platform** waiting to be born. The stress-glucose prediction engine Joe is building for Keli is the exact technology that 30 million GLP-1 users will need by 2030. Nobody else is building it. Build for one. Scale to millions. That's the Buffett way — start with what you know (Keli's T1D), prove the model, then deploy capital into the massive adjacent market. The GLP-1 market is a $200 billion tidal wave. Joe's app is a surfboard. 🏄‍♂️ --- *"The best businesses are born from solving your own problem first." — Every successful founder ever* 🦞